PedAM
Pediatric Disease Annotations & Medicines
| Disease | leukemia |
| Phenotype | C0023484|plasma cell leukemia |
| Sentences | 1 |
| PubMedID- 20938660 | The exclusion criteria were (1) a diagnosis of any acute or chronic leukemia (including plasma cell leukemia) or myelodysplastic syndrome (for patients with mm, a pb smear was evaluated within 24 h before the first dose of plerixafor; patients who showed the presence of plasma cells or blasts that indicated plasma cell leukemia should have been excluded from receiving plerixafor; (2) a co-morbid condition that, in the view of the treating physician, rendered the patient at high risk from treatment complications; (3) vasculitis or autoimmune disease; (4) brain metastases, carcinomatous meningitis, or any other malignancy, unless the patient had been free of disease for at least 5 years following therapy with curative intent; (5) clinically significant heart disease, e.g., as indicated by results of an electrocardiography or other study (exercise study, scan) that were suggestive of previously undiagnosed cardiac ischemia, or a history of clinically significant rhythm disturbance (arrhythmia) or other conduction abnormality in the last year; (6) acute infection and/or fever (body temperature >38°c); (7) hypercalcemia (>1 mg/dl above the upper limit of normal); (8) pregnancy or breastfeeding among women; (9) lack of willingness among patients (male and female) with child-bearing potential to implement adequate birth control; (10) known hiv infection; (11) obesity exceeding 175% of ideal body weight; and (12) receipt of experimental treatment during mobilization. |
Page: 1